BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 36018392)

  • 1. DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients.
    Vasiyani H; Mane M; Rana K; Shinde A; Roy M; Singh J; Gohel D; Currim F; Srivastava R; Singh R
    Apoptosis; 2022 Dec; 27(11-12):961-978. PubMed ID: 36018392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers.
    Hong C; Schubert M; Tijhuis AE; Requesens M; Roorda M; van den Brink A; Ruiz LA; Bakker PL; van der Sluis T; Pieters W; Chen M; Wardenaar R; van der Vegt B; Spierings DCJ; de Bruyn M; van Vugt MATM; Foijer F
    Nature; 2022 Jul; 607(7918):366-373. PubMed ID: 35705809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The analog of cGAMP, c-di-AMP, activates STING mediated cell death pathway in estrogen-receptor negative breast cancer cells.
    Vasiyani H; Shinde A; Roy M; Mane M; Singh K; Singh J; Gohel D; Currim F; Vaidya K; Chhabria M; Singh R
    Apoptosis; 2021 Jun; 26(5-6):293-306. PubMed ID: 33840002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage-triggered activation of cGAS-STING pathway induces apoptosis in human keratinocyte HaCaT cells.
    Li C; Liu W; Wang F; Hayashi T; Mizuno K; Hattori S; Fujisaki H; Ikejima T
    Mol Immunol; 2021 Mar; 131():180-190. PubMed ID: 33423764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS-STING pathway.
    Guo Y; Shen R; Wang F; Wang Y; Xia P; Wu R; Liu X; Ye W; Tian Y; Wang D
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6315-6328. PubMed ID: 36745223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage.
    Cheon H; Holvey-Bates EG; McGrail DJ; Stark GR
    Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34799452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways.
    Chuangchot N; Jamjuntra P; Yangngam S; Luangwattananun P; Thongchot S; Junking M; Thuwajit P; Yenchitsomanus PT; Thuwajit C
    Breast Cancer Res; 2023 Jul; 25(1):86. PubMed ID: 37480115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
    Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
    Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
    Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
    Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.
    Lee KM; Lin CC; Servetto A; Bae J; Kandagatla V; Ye D; Kim G; Sudhan DR; Mendiratta S; González Ericsson PI; Balko JM; Lee J; Barnes S; Malladi VS; Tabrizi S; Reddy SM; Yum S; Chang CW; Hutchinson KE; Yost SE; Yuan Y; Chen ZJ; Fu YX; Hanker AB; Arteaga CL
    Cancer Immunol Res; 2022 Jul; 10(7):829-843. PubMed ID: 35561311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
    Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
    Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
    Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
    Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer.
    Lin M; Cai Y; Chen G; Zhong H; Li B; Li T; Xiao Z; Shuai X
    Biomaterials; 2023 May; 296():122067. PubMed ID: 36854221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer.
    Haq ATA; Yang PP; Jin C; Shih JH; Chen LM; Tseng HY; Chen YA; Weng YS; Wang LH; Snyder MP; Hsu HL
    Theranostics; 2024; 14(5):2167-2189. PubMed ID: 38505617
    [No Abstract]   [Full Text] [Related]  

  • 18. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer.
    Hu Y; Manasrah BK; McGregor SM; Lera RF; Norman RX; Tucker JB; Scribano CM; Yan RE; Humayun M; Wisinski KB; Tevaarwerk AJ; O'Regan RM; Wilke LG; Weaver BA; Beebe DJ; Jin N; Burkard ME
    Mol Cancer Ther; 2021 Dec; 20(12):2553-2567. PubMed ID: 34583980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.